SI1181027T1 - Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria - Google Patents

Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria

Info

Publication number
SI1181027T1
SI1181027T1 SI200030363T SI200030363T SI1181027T1 SI 1181027 T1 SI1181027 T1 SI 1181027T1 SI 200030363 T SI200030363 T SI 200030363T SI 200030363 T SI200030363 T SI 200030363T SI 1181027 T1 SI1181027 T1 SI 1181027T1
Authority
SI
Slovenia
Prior art keywords
hyperoxaluria
dietary
prevention
treatment
pharmaceutical composition
Prior art date
Application number
SI200030363T
Other languages
English (en)
Slovenian (sl)
Inventor
Simone Claudio De
Original Assignee
Actial Farmaceutica Lda.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actial Farmaceutica Lda. filed Critical Actial Farmaceutica Lda.
Publication of SI1181027T1 publication Critical patent/SI1181027T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
SI200030363T 1999-05-28 2000-05-24 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria SI1181027T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999RM000338A IT1309427B1 (it) 1999-05-28 1999-05-28 Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
PCT/IT2000/000213 WO2000072855A2 (en) 1999-05-28 2000-05-24 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
EP00935478A EP1181027B1 (en) 1999-05-28 2000-05-24 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria

Publications (1)

Publication Number Publication Date
SI1181027T1 true SI1181027T1 (en) 2004-08-31

Family

ID=11406789

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030363T SI1181027T1 (en) 1999-05-28 2000-05-24 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria

Country Status (34)

Country Link
US (2) US6562336B2 (xx)
EP (1) EP1181027B1 (xx)
JP (1) JP4737836B2 (xx)
KR (1) KR100781703B1 (xx)
CN (1) CN100350919C (xx)
AR (1) AR024555A1 (xx)
AT (1) ATE265857T1 (xx)
AU (1) AU773459B2 (xx)
BR (1) BR0011038B1 (xx)
CA (1) CA2373255C (xx)
CZ (1) CZ20014076A3 (xx)
DE (1) DE60010456T2 (xx)
DK (1) DK1181027T3 (xx)
DZ (1) DZ3165A1 (xx)
EA (1) EA004257B1 (xx)
EE (1) EE200100618A (xx)
ES (1) ES2219344T3 (xx)
HK (1) HK1048066B (xx)
HU (1) HU225134B1 (xx)
IL (3) IL146703A0 (xx)
IS (1) IS6150A (xx)
IT (1) IT1309427B1 (xx)
MA (1) MA26790A1 (xx)
MX (1) MXPA01012184A (xx)
NO (1) NO20015782L (xx)
NZ (1) NZ516020A (xx)
PL (1) PL352014A1 (xx)
PT (1) PT1181027E (xx)
SI (1) SI1181027T1 (xx)
SK (1) SK16612001A3 (xx)
TR (1) TR200103439T2 (xx)
UA (1) UA71621C2 (xx)
WO (1) WO2000072855A2 (xx)
ZA (1) ZA200110504B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US8697051B2 (en) * 1999-06-09 2014-04-15 Vsl Pharmaceuticals Inc. Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
US9655932B2 (en) 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
EP1649863A1 (en) * 2003-06-24 2006-04-26 Otsuka Pharmaceutical Co., Ltd. Composition for lowering serum uric acid level
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
AU2005224162A1 (en) 2004-03-19 2005-09-29 Danisco A/S Emulsifier composition for shortening
EP1814995A2 (en) * 2004-10-27 2007-08-08 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
EP1962873B1 (en) * 2005-12-14 2013-05-29 OxThera, Inc., Pharmaceutical compositions comprising oxalate-reducing bacteria
AU2006329844B2 (en) * 2005-12-16 2012-11-15 Oxthera Intellectual Property Ab Compositions and methods for oxalate reduction
EP2129385A2 (en) * 2007-03-27 2009-12-09 The Procter & Gamble Methods and kits for administering probiotics
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN101606952B (zh) * 2008-06-17 2012-09-19 上海交通大学医学院附属第三人民医院 乳双歧杆菌在制备预防泌尿系统结石药物中的应用
EP2338976B1 (en) 2008-09-30 2017-08-16 Meiji Co., Ltd. Lactic acid bacterium having high oxalic acid decomposition ability
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110791A1 (it) * 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
ITMI20121173A1 (it) * 2012-07-04 2014-01-05 Neupharma Srl Composizioni dietetiche e/o farmaceutiche comprendenti ceppi di lactobacillus e bifidobacterium capaci di degradare gli ossalati e di indurre una risposta immunitaria di tipo anti-infiammatorio
ITMI20130795A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici e/o bifidobatteri per uso nel trattamento preventivo e/o curativo delle infezioni batteriche e/o delle infiammazioni del tratto urinario e/o della prostata che sono la causa di prostatiti e ipertrofia prostat
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
JP5765832B2 (ja) * 2013-12-26 2015-08-19 雪印メグミルク株式会社 加齢に伴う代謝異常症の予防・改善・治療剤
PL3237600T3 (pl) * 2014-10-01 2020-11-16 Triphase Pharmaceuticals Pvt. Ltd. Termostabilne szczepy, ich produkty i sposoby stosowania
ITUB20155752A1 (it) * 2015-11-19 2017-05-19 Probiotical Spa Composizione di batteri per uso per attenuare le diminuzioni di prestazione dopo un esercizio fisico che danneggia i muscoli.
CN107868775A (zh) 2016-09-23 2018-04-03 武汉康复得生物科技股份有限公司 草酸脱羧酶的制备及其制品和应用
WO2018125735A1 (en) 2016-12-29 2018-07-05 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
EP3894564A4 (en) * 2018-12-10 2022-09-14 Novome Biotechnologies, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPEROXALURIA
CN113308416B (zh) * 2021-07-20 2023-02-24 四川大学 一株具有抑制肾结石形成能力的植物乳杆菌及其应用
CN115851508B (zh) * 2022-10-13 2024-01-09 山东中科嘉亿生物工程有限公司 一种降草酸、改善肾结石的嗜热链球菌jyst-26及其产品、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810520A (ja) * 1981-07-10 1983-01-21 Miyarisan Kk 胆石症の治療薬
EP0577904B1 (fr) * 1992-07-06 1997-05-14 Societe Des Produits Nestle S.A. Bactérie lactique
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
EP0856259B1 (en) * 1996-12-23 1998-08-12 SITIA-YOMO S.p.A. Composition for feed use comprising lyophilized live lactic bacteria
EP2033651A1 (en) * 1997-05-23 2009-03-11 OxThera, Inc., Oxalate-degrading microorganisms or oxalate-degrading enzymes for preventing oxalate related disease
RU2139346C1 (ru) * 1999-03-02 1999-10-10 Шендеров Борис Аркадьевич Штамм бактерий lactobacillus plantarum, обладающий способностью снижать уровень оксалата и используемый для приготовления препаратов и продуктов питания для профилактики и лечения гипероксалурии

Also Published As

Publication number Publication date
EP1181027B1 (en) 2004-05-06
IL199437A0 (en) 2011-07-31
USRE39585E1 (en) 2007-04-24
TR200103439T2 (tr) 2002-06-21
EP1181027A2 (en) 2002-02-27
UA71621C2 (en) 2004-12-15
DZ3165A1 (fr) 2000-12-07
ITRM990338A0 (it) 1999-05-28
EA200101262A1 (ru) 2002-04-25
NO20015782D0 (no) 2001-11-27
DK1181027T3 (da) 2004-08-16
IT1309427B1 (it) 2002-01-23
HK1048066A1 (en) 2003-03-21
NO20015782L (no) 2002-01-25
SK16612001A3 (sk) 2002-04-04
IL146703A0 (en) 2002-07-25
EE200100618A (et) 2003-02-17
US20020061292A1 (en) 2002-05-23
DE60010456T2 (de) 2005-05-12
PT1181027E (pt) 2004-09-30
WO2000072855A2 (en) 2000-12-07
KR20020019918A (ko) 2002-03-13
ES2219344T3 (es) 2004-12-01
BR0011038A (pt) 2002-02-26
HU225134B1 (en) 2006-06-28
ATE265857T1 (de) 2004-05-15
MA26790A1 (fr) 2004-12-20
NZ516020A (en) 2003-06-30
HUP0201409A2 (en) 2002-08-28
CN100350919C (zh) 2007-11-28
AU773459B2 (en) 2004-05-27
CA2373255C (en) 2010-01-19
IL199437A (en) 2016-10-31
JP2003500451A (ja) 2003-01-07
HUP0201409A3 (en) 2004-10-28
JP4737836B2 (ja) 2011-08-03
DE60010456D1 (de) 2004-06-09
PL352014A1 (en) 2003-07-14
US6562336B2 (en) 2003-05-13
CZ20014076A3 (cs) 2002-03-13
BR0011038B1 (pt) 2014-02-18
CN1365284A (zh) 2002-08-21
EA004257B1 (ru) 2004-02-26
IL146703A (en) 2010-03-28
HK1048066B (zh) 2008-08-01
ITRM990338A1 (it) 2000-11-28
CA2373255A1 (en) 2000-12-07
ZA200110504B (en) 2002-09-25
WO2000072855A3 (en) 2001-06-28
AR024555A1 (es) 2002-10-16
AU5101600A (en) 2000-12-18
IS6150A (is) 2001-11-08
MXPA01012184A (es) 2003-06-30
KR100781703B1 (ko) 2007-12-03

Similar Documents

Publication Publication Date Title
IL146703A0 (en) Dietary of pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
HK1046240A1 (en) Pharmaceutical compositions for the treatment of insulin resistance
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
AU7449598A (en) Medicinal composition for prevention or treatment of hepatopathy
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
HUP0003851A3 (en) Pharmaceutical composition for the treatment or prevention of glomerulopathy
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
PL354413A1 (en) Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts ofginkgo biloba
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
HU0500865D0 (en) Use of teophyllin derivatives for the preparation of pharmaceutical compositions for the prevention and treatment of shock
IL147410A0 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
GB9602444D0 (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU5416500A (en) Pharmaceutical composition for the treatment of calcification
HUP0300313A3 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
IL143903A0 (en) Use of phanquinone for the treatment or prevention of memory impairment
HUP0301847A3 (en) Use of adatanserin for producing pharmaceutical compositions for the treatment and prevention of neurodegenerative conditions
IL127102A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IL137190A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IL122883A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
AU4222400A (en) Methods and compositions for the treatment and prevention of lung disease
SI1408966T1 (sl) Sinergistične farmacevtske kombinacije za preprečevanje ali zdravljenje diabetesa